Published on 21/12/2025
How to Choose the Right Preferred Term (PT) in MedDRA Coding
Why Preferred Term Selection Matters
The Preferred Term (PT) is the cornerstone of MedDRA coding in clinical trials and pharmacovigilance. Each PT represents a unique medical concept that enables harmonized reporting of adverse events across studies and regions. The correct choice of PT ensures regulatory compliance, supports accurate signal detection, and allows for meaningful safety analysis. Conversely, misclassification at the PT level can lead to erroneous safety conclusions, missed signals, or regulatory findings during inspections.
For example, if an investigator records “fits,” coders must map this to the PT “Convulsion.” Selecting “Epilepsy” instead would be inappropriate because epilepsy implies a chronic condition, not an acute event. Regulators such as the FDA, EMA, and CDSCO expect sponsors to have robust processes and SOPs to ensure accuracy in PT selection.
Since PTs are used in aggregate safety reports such as DSURs, PSURs, and IND safety reports, the reliability of these submissions depends on consistent and accurate PT coding. Training coders and establishing coding conventions are therefore essential.
Process of Selecting a Preferred Term
Coders usually begin with the investigator-reported term, which is mapped to the
The selection process typically involves:
- Reviewing the verbatim term: Understand context and clinical meaning.
- Identifying LLT matches: Search MedDRA for possible LLTs that fit.
- Evaluating PT linkage: Ensure the LLT maps to the most accurate PT.
- Applying coding conventions: Follow sponsor or CRO guidelines for standardization.
- Quality check: Verify accuracy through peer review or safety database controls.
For example, the investigator term “stomach upset” could map to LLTs such as “Abdominal discomfort” or “Dyspepsia.” The coder must select the PT that best reflects the clinical description, likely “Dyspepsia.”
Examples of Correct PT Selection
Below is a table illustrating how PTs should be chosen for different investigator terms:
| Investigator Term | Possible LLTs | Selected PT | Rationale |
|---|---|---|---|
| Fits | Fits, Seizures | Convulsion | Represents acute seizure event, not chronic epilepsy |
| Low white blood cells | Leukopenia, Low WBC count | Neutropenia | Clinical context usually indicates neutrophil reduction |
| Skin rash | Rash, Erythematous rash | Rash | General PT applied for dermatologic adverse events |
| Heart attack | Heart attack | Myocardial infarction | Clinical diagnosis of acute coronary syndrome |
These examples show that careful PT selection maintains the clinical intent of the original term while ensuring regulatory-standard consistency.
Challenges in Choosing the Right PT
Despite clear rules, coders often face challenges in selecting PTs:
- Ambiguity: Investigator terms may be vague, such as “feeling unwell,” which lacks clinical specificity.
- Multiple options: Several LLTs may map to different PTs, requiring coder judgment.
- Updates in MedDRA: New PTs are introduced in biannual updates, requiring re-coding or reconciliation.
- Inter-coder variability: Different coders may select different PTs for the same verbatim term.
- System errors: Automated coding tools may misclassify terms without proper review.
For example, “fainting” could map to PTs such as “Syncope” or “Loss of consciousness.” Choosing the right PT depends on clinical context. Without clear conventions, inconsistencies may arise across studies.
Regulatory Expectations and Inspection Findings
Regulators expect traceability and consistency in PT selection. Common inspection findings include:
- Incorrect mapping of investigator terms to PTs.
- Lack of documentation for coding decisions.
- Failure to update PT assignments after MedDRA version upgrades.
- Inconsistent PT use across trials, leading to skewed safety analyses.
For example, an inspection may reveal that the same investigator term “blood clot” was coded as “Thrombosis” in one study and “Embolism” in another. Regulators view this as a major compliance gap. Sponsors are expected to have coding conventions and regular audits to prevent such inconsistencies.
Best Practices for PT Selection
To ensure accuracy in MedDRA coding, clinical teams should adopt these best practices:
- Develop detailed coding conventions with examples for common terms.
- Train coders and CRAs regularly on MedDRA updates and PT selection principles.
- Use hybrid auto/manual coding to balance efficiency with accuracy.
- Perform peer reviews and audits of coded terms to identify errors.
- Reconcile coding across studies to maintain consistency in aggregate reporting.
External resources such as the ClinicalTrials.gov database provide examples of standardized safety reporting, reinforcing the importance of accurate coding practices.
Key Takeaways
Choosing the right PT in MedDRA coding is critical for regulatory compliance, safety analysis, and inspection readiness. Clinical teams must:
- Understand the MedDRA hierarchy and its linkages from LLT to PT.
- Apply clear conventions to reduce ambiguity in coding.
- Ensure PT selection reflects the true clinical meaning of investigator terms.
- Document and audit coding decisions for consistency across trials.
- Stay updated with MedDRA version changes and retrain staff accordingly.
By applying these principles, sponsors and CROs can ensure that safety data is accurate, consistent, and aligned with global regulatory expectations.